Drugs / hOMSC300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05698017 | Nov 2022 → Feb 2026 overdue | multiple system atrophy | Cytora Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hOMSC300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05698017 ↗ |
| Modality | Cell therapy | “Allogeneic Cell Therapy Product” NCT05698017 ↗ |
| Route | Intrathecal | “intrathecal administration” NCT05698017 ↗ |